Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemisinin 500 mg in mild to moderate COVID-19
NCT05004753Phase 4Completed
- Sponsor
- Oncotelic Therapeutics, Inc.
- Start
- Sep 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of artemisinin in coronavirus disease 2019 (COVID-19), sponsored by Oncotelic Therapeutics, Inc.. Started Sep 2020; status: completed.
02
Drugs
artemisinin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05004753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004753.